Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, between 18 years and 65 years of age.~2. Investigator assessment of the acne scarring on each cheek of moderate to severe.~3. A history of acne scarring for more than 3 years.~4. Subject assesses the appearance of both sides of their facial acne scars as dissatisfied or very dissatisfied with appearance.~Exclusion Criteria:~1. Significant active acne.~2. Use of oral antibiotic or retinoid active acne therapy within one year of enrollment.~3. Presence of hypertrophic scars on the cheeks.~4. More than 20% of treatment area comprised of ice pick scars or sinus tracts~5. Treatment area per cheek is less than 9 cm x cm~6. Unilateral or unbalanced acne scar distribution.~7. Physical attributes which prevent the assessment or treatment of the acne scars.~8. Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study.~9. Previous treatment with Isolagen TherapyTM.~10. Use of Isotretinoin within one year of enrollment into study.~11. Use of permanent or semi-permanent dermal fillers in the treatment areas within defined time frames.~12. Disorders or drugs that increase bleeding or clotting.~13. Pregnant or lactating women or women trying to become pregnant during the study.~14. Excessive exposure to sun.~15. Smoking more than ½ pack of cigarettes per day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Double blinded active (Type: EXPERIMENTAL): Subject will receive autologous fibroblast treatment on either their left or right side of their face
- Double blinded placebo (Type: PLACEBO_COMPARATOR): Subject will receive placebo treatment on the opposite side of the face from active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).